An observational study in Frailty, Frailty Syndrome and Emergency Department, sponsored by University Hospital, Linkoeping. Completed at 1 site in Sweden. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2022-06-23.
Sponsored by University Hospital, Linkoeping · Observational
This prospective observational study will investigate the correlation of frailty in relation to serious outcomes. Serious outcomes are defined as: mortality within 30 days, admission to hospital, length of stay in the Emergency Department(ED), in hospital length of stay and revisits to the ED.
The exposure, frailty, will be assessed according to Clinical Frailty Scale. ED patients >65 years of age in a Swedish regional health care system (Region Östergötland, Sweden) comprising three EDs in Linköping, Norrköping and Motala. The outcomes will be compared according to the degree of frailty and censored over 7, 30 and 90 days respectively.
Frailty is a common clinical syndrome in older adults that carries an increased risk for poor health outcomes including falls, incident disability, hospitalization, and mortality.
The clinical frailty scale (CFS) is a measure of frailty based on clinical judgement in a 9 level scale, categorized as "vulnerable" (1-4), "mildly frail" (5), moderatly frail (6) and severely and very severely frail (7-8).". A validation study of the CFS in community-dwelling older people showed that it performed better than measures of cognition, function or comorbidity in assessing risk for death. In a prospective observational study including consecutive ED patients aged 65 years or older The Hosmer-Lemeshow test indicated a good agreement between predicted probability and observed frequency of 30-day mortality and ICU admission.
The aim of this study will be to investigate if the fraily, assessed according to CFS, is associated with increased 30-day mortality. in a Swedish Emergency Care context. Secondary outcomes included 7-and 90-day mortality, ED length of stay, hospital admission, hospital length of stay, subsequent falls and medication changes. Additionally, we collect data on morbidity and comorbidities to assess the association with the level of frailty. Since this is a multicenter study, possible geographic differences will be studied as well. Based on the results of this study, possible interventions could be identified to improve the care of the frail geriatric patients presenting at the ED.
1,692 studies on the registry are indexed under Emergencies; 333 are open to participants now.
This study's enrollment of 1,800 is above the median of 353 across 714 observational studies indexed under Emergencies.
Browse Emergencies studies →University Hospital, Linkoeping is the lead sponsor of 118 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients of all genders at the age of ≥65 years seeking medical care at the three ED instances in Region Östergötland.
Exclusion Criteria:
Mortality in 30 days
Investigate level of mortality in cohort at 30 days
Time frame: All cause mortality up to 90 days from index visit
Mortality in 7 and 90 days
Investigate level of mortality in cohort at 7 and 90 days
Time frame: All cause mortality up to 90 days from index visit
Admission to hospital
Investigate level of all cause admissions in cohort
Time frame: Hospital admission on index visit, censored at 90 days
ED length of stay
Investigate length of stay at ED
Time frame: Length of stay at ED, censored at 4 days
Hospital length of stay
Investigate hospital length of stay
Time frame: Hospital length of stay from index visit, censored at 90 days
Revisitis to the ED
Number of newly registered visits to the emergency department after index visit
Time frame: Number of newly registered visits to the emergency department after index visit, censored at 90 days
Fall prevalence after the index visit
Falls that resulted in further ED visits
Time frame: Falls that resulted in further ED visits after index visit, censored in 90 days
Alterations in medication during the visit (based on codes for Anatomical, Therapeutic, Chemical classification (ATC-code))
Alterations in medication and during the follow-up period
Time frame: Alterations in medications from index visit and during the follow-up period, censored at 90 days
Plan to share: No
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Linkoeping